In 2012, we presented a new approach—encapsulated cell biodelivery (ECB) technology, as an alternative to deliver human mature (hm) NGF, aiming to halt the degeneration of cholinergic neurons in the basal forebrain and improve overall cholinergic function in AD patients [16,17]. Here, NGF is linked to Alzheimer disease.